 Lixte Biotechnology Holdings Inc NASDAQ: LIXT has announced that its lead compound, LB-100, a protein phosphatase 2A PP2A inhibitor, was reported to enhance the effectiveness of elements of standard therapy in models of small cell lung cancer SCLC. Dr. Ravi Salgia is the papers corresponding author. 